Table of Contents
Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, often requires treatment with biologic therapies. These medications have revolutionized disease management but come with potential risks, notably infections.
Understanding IBD Biologics
Biologics are targeted therapies that modulate the immune system to reduce inflammation. Common biologics include anti-TNF agents such as infliximab and adalimumab, as well as newer agents like vedolizumab and ustekinumab.
Risks of Infection
While effective, biologics suppress parts of the immune response, increasing susceptibility to infections. Patients may experience bacterial, viral, fungal, or opportunistic infections during treatment.
Common Infections
- Respiratory infections
- Urinary tract infections
- Herpes zoster and other viral reactivations
- Fungal infections such as candidiasis
Serious Infections
- Sepsis
- Reactivation of latent tuberculosis
- Opportunistic infections like Pneumocystis jirovecii pneumonia
Counseling Strategies
Effective patient counseling involves discussing the benefits and risks of biologic therapy, emphasizing infection prevention, and recognizing early signs of infection.
Pre-Treatment Evaluation
- Screen for latent tuberculosis with a tuberculin skin test or IGRA
- Assess for hepatitis B and C infections
- Review vaccination history
Patient Education
- Advise on the importance of hand hygiene
- Encourage timely vaccination updates, including influenza and pneumococcal vaccines
- Inform about signs of infection such as fever, cough, or urinary symptoms
Monitoring During Therapy
- Regular clinical assessments for infection symptoms
- Laboratory monitoring as indicated
- Immediate evaluation if infection is suspected
Conclusion
While biologics are highly effective for managing IBD, understanding and communicating the risks of infection are vital. Proper screening, vaccination, patient education, and monitoring can significantly mitigate these risks and ensure safe treatment outcomes.